MannKind (MNKD) Stock Price, News & Analysis

Company Overview

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com.

Key Stats

• Today's Range: $3.41 to $3.60
• 50-Day Range: $2.37 to $3.77
• 52-Week Range: $2.23 to $6.51
• Volume: 4.91 million shs
• Average Volume: 5.11 million shs
• Market Capitalization: $1.10 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.97
• Consensus Rating: Moderate Buy

MannKind Stock Analysis - MarketRank™

MannKind scored higher than 72% of companies evaluated by MarketBeat, and ranked 162nd out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MannKind has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

MannKind has a consensus price target of $8.97, representing about 151.2% upside from its current price of $3.57.

Amount of Analyst Coverage

MannKind has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MannKind are expected to grow in the coming year, from ($0.06) to $0.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MannKind is -50.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MannKind is -50.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.08% of the float of MannKind has been sold short.

Short Interest Ratio / Days to Cover

MannKind has a short interest ratio ("days to cover") of 4.96.

Change versus previous month

Short interest in MannKind has recently increased by 3.19%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MannKind does not currently pay a dividend.

Dividend Growth

MannKind does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.73

News Sentiment

MannKind has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for MannKind this week, compared to 5 articles on an average week.

Search Interest

Only 8 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $203,267.00 in company stock, which represents 0.0184% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, MannKind insiders have bought 364.72% more of their company's stock than they have sold. Specifically, they have bought $259,000.00 in company stock and sold $55,733.00 in company stock.

Percentage Held by Insiders

2.60% of the stock of MannKind is held by insiders.

Percentage Held by Institutions

49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 6/09/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MNKD
• CIK: 899460
• Web: www.mannkindcorp.com
• Phone: (818) 661-5000
• Fax: 661-775-2081
• Employees: 400
• Year Founded: 1991

Price Target and Rating

• Average Price Target for MannKind: $8.97
• High Price Target: $15.00
• Low Price Target: $4.75
• Potential Upside/Downside: +151.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $5.86 million
• Net Margins: -6.63%
• Pretax Margin: -7.92%
• Return on Equity: -11.21%
• Return on Assets: -3.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.87
• Quick Ratio: 1.50

Sales & Book Value

• Annual Sales: $348.97 million
• Price / Sales: 3.16
• Cash Flow: $0.07 per share
• Price / Cash Flow: 54.78
• Book Value: ($0.17) per share
• Price / Book: -21.00

Miscellaneous

• Outstanding Shares: 308,950,000
• Free Float: 300,917,000
• Market Cap: $1.10 billion
• Optionable: Optionable
• Beta: 1.13